Abstract
Native α1-adrenoreceptors (ARs) appear to exist as three different subtypes encoded by three genes, α1A/1a, α1B/1b, and α1D/1d. Historically, the discovery of agents selective for each of the three α1-AR subtypes has been an active area of medicinal chemistry research because of the wide number of possible therapeutic applications. Initially introduced for the management of hypertension, α1-AR antagonists have, in fact, become increasingly common in the treatment of benign prostatic hyperplasia (BPH), and are effective therapeutic tools, when characterized by an appropriate uroselective profile. The majority of these derivatives display a competitive mechanism of action and belong to a variety of structural classes, but this review is focused on compounds belonging to the quinazoline, benzodioxane, arylpiperazine, and 1,4- dihydropyridine classes.
Keywords: Alpha-1 adrenoreceptors, alpha-1 adrenergic antagonists, quinazolines, benzodioxanes, arylpiperazines, 1,4- dihydropyridines
Current Topics in Medicinal Chemistry
Title: Recent Advances in α1-Adrenoreceptor Antagonists as Pharmacological Tools and Therapeutic Agents
Volume: 7 Issue: 2
Author(s): Michela Rosini, Maria L. Bolognesi, Dario Giardina, Anna Minarini, Vincenzo Tumiatti and Carlo Melchiorre
Affiliation:
Keywords: Alpha-1 adrenoreceptors, alpha-1 adrenergic antagonists, quinazolines, benzodioxanes, arylpiperazines, 1,4- dihydropyridines
Abstract: Native α1-adrenoreceptors (ARs) appear to exist as three different subtypes encoded by three genes, α1A/1a, α1B/1b, and α1D/1d. Historically, the discovery of agents selective for each of the three α1-AR subtypes has been an active area of medicinal chemistry research because of the wide number of possible therapeutic applications. Initially introduced for the management of hypertension, α1-AR antagonists have, in fact, become increasingly common in the treatment of benign prostatic hyperplasia (BPH), and are effective therapeutic tools, when characterized by an appropriate uroselective profile. The majority of these derivatives display a competitive mechanism of action and belong to a variety of structural classes, but this review is focused on compounds belonging to the quinazoline, benzodioxane, arylpiperazine, and 1,4- dihydropyridine classes.
Export Options
About this article
Cite this article as:
Rosini Michela, Bolognesi L. Maria, Giardina Dario, Minarini Anna, Tumiatti Vincenzo and Melchiorre Carlo, Recent Advances in α1-Adrenoreceptor Antagonists as Pharmacological Tools and Therapeutic Agents, Current Topics in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/156802607779318244
DOI https://dx.doi.org/10.2174/156802607779318244 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension and Ischemic Heart Disease in Women
Current Pharmaceutical Design Rottlerin: Bases for a Possible Usage in Psoriasis
Current Drug Metabolism The Use of Sensory Nerve Stimulation and Compression Bandaging to Improve Sensory Nerve Function and Healing of Chronic Venous Leg Ulcers
Current Aging Science Modulation of Gi Proteins in Hypertension: Role of Angiotensin II and Oxidative Stress
Current Cardiology Reviews Evaluation of LVDD by CCTA with Dual-source CT in Type 2 Diabetes Mellitus Patients
Current Medical Imaging The Pulmonary Renin-Angiotensin System
Current Pharmaceutical Design Depression and its Relation with Uncontrolled Hypertension and Increased Cardiovascular Risk
Current Hypertension Reviews Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review
Current Drug Abuse Reviews Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic Syndrome
Current Pharmaceutical Design Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Effect of Fenofibrate on the Concentration and Relative Distribution of LDL Subfractions in Patients with Combined Dyslipidemia
Letters in Drug Design & Discovery New Treatments for COPD in the Elderly
Current Pharmaceutical Design Forward and Backward Aortic Components and Reflection Indexes in Children and Adolescents: Determinants and Role in High Pressure States
Current Hypertension Reviews Subpopulations of Bone Marrow Mesenchymal Stem Cells Exhibit Differential Effects in Delaying Retinal Degeneration
Current Molecular Medicine Contractile Mechanisms in Diabetes-Related Erectile Dysfunction
Current Pharmaceutical Design A Rationale for Combined Therapy with a Calcium Channel Blocker and a Statin: Evaluation of Basic and Clinical Evidence
Current Drug Targets - Cardiovascular & Hematological Disorders Prostacyclin, Atherothrombosis, and Cardiovascular Disease
Current Medicinal Chemistry A Neurotrophic Rationale for the Therapy of Neurodegenerative Disorders
Current Alzheimer Research Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets